The National Drug Abuse Treatment Clinical Trials Network
The summary for the The National Drug Abuse Treatment Clinical Trials Network grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
The National Drug Abuse Treatment Clinical Trials Network: The National Institute on Drug Abuse (NIDA) invites cooperative agreement applications from established clinical investigators to participate in the National Drug Abuse Treatment Clinical Trials Network (CTN). Applications from geographic areas not currently well represented in the CTN are particularly encouraged. This Request for Applications (RFA) is the fourth solicitation for participation in the CTN. It is intended for both new applications and competing continuations. As a nation-wide partnership among drug abuse treatment providers, researchers, and NIDA staff, the mission of the CTN is to conduct studies of behavioral, pharmacological, and integrated behavioral and pharmacological treatment interventions in rigorous, multi-site clinical trials to determine the effectiveness of these interventions across a broad range of community- based treatment settings and diverse patient populations. The CTN disseminates and promotes the adoption of proven treatments to physicians, providers, their patients, accrediting bodies, educational institutions, policy makers and funders to improve the quality of drug abuse treatment throughout the country, using science as the vehicle. CTN clinical trials are carried out in community-based treatment settings. Each awardee functions as a CTN Research Node, consisting of a Regional Research and Training Center (RRTC) that is linked in partnership with community-based treatment programs (CTPs). The CTN consists of multiple Nodes, and each Node works in concert with other Nodes and NIDA to conduct multi-site clinical trials research. Awardees deliver and test an array of both behavioral and pharmacological treatments and determine conditions under which novel and efficacious treatments are successfully adopted. Studies span multiple sites engaging diverse patient populations in dispersed geographical regions. As a cooperative agreement, there is substantial NIDA involvement in the management and administration of the CTN. Current CTN Nodes are located in California, Colorado, Connecticut, Florida, Maryland, Massachusetts, Michigan, New Mexico, New York, North Carolina, Ohio, Oregon, Pennsylvania, South Carolina, and Washington. NIDA recognizes a benefit in a greater geographic distribution of CTN sites as well as a desire to encompass more subpopulations of minority groups and to broaden the range of treatment providers who work under varying systems of reimbursement and organization of care. By expanding in these areas, greater variety in the types of studies conducted and greater confidence in the generalizability of those studies will be assured. Therefore, as noted, one purpose of this Request for Applications (RFA) is to expand the geographic distribution of CTN sites, and applications are encouraged from investigators in those geographic areas without CTN Nodes and where the CTN is not well represented. Another purpose is to enable eleven existing Nodes to re-compete to continue participation within the CTN for another five years.
|Federal Grant Title:||The National Drug Abuse Treatment Clinical Trials Network|
|Federal Agency Name:||National Institutes of Health|
|Grant Categories:||Health Education|
|Type of Opportunity:||Discretionary|
|Funding Opportunity Number:||RFA-DA-05-001|
|Type of Funding:||Cooperative Agreement|
|CFDA Descriptions:||Drug Abuse Research Programs|
|Current Application Deadline:||No deadline provided|
|Original Application Deadline:||Oct 14, 2004|
|Posted Date:||Jul 12, 2004|
|Creation Date:||Jul 12, 2004|
|Archive Date:||Nov 13, 2004|
|Total Program Funding:|
|Maximum Federal Grant Award:||$700,000|
|Minimum Federal Grant Award:|
|Expected Number of Awards:|
|Cost Sharing or Matching:||No|
- Applicants Eligible for this Grant
- State governments County governments City or township governments Special district governments Independent school districts Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education For profit organizations other than small businesses Small businesses
- Link to Full Grant Announcement
- Information not provided
- Grant Announcement Contact
- If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster FBOWebmaster@OD.NIH.GOV NIH OER Webmaster
- Similar Government Grants
- • Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01)
- • New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R01 Clinical Tria...
- • New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R34 - Clinical Tr...
- • NIDA Core "Center of Excellence" Grant Program (P30 Clinical Trial Optional)
- • Using Human Cell Animal Chimera Brains to Study HIV Latency and Pathology R01 - Clinical T...
- • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards
- • Drug Abuse Aspects of Hiv/Aids and Other Infections
- • Epidemiology of Drug Abuse
- More Grants from the National Institutes of Health
- • Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Administrative Resource...
- • Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Research Resource (U24)...
- • New Cohorts for Environmental Exposures and Cancer Risk (CEECR; UG3/UH3 Clinical Trial Not...
- • Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical ...
- • Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Tria...